Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.82 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.82 |
| ▸ | PARP1 | P09874 | 18/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61589 | 0.94 | PIM1 (0.85) | PIM1CSNK1DPARP1KMT2A | |
| SCHEMBL61598 | 0.91 | PARP1 (0.82) | PIM1CSNK1DPARP1KMT2A | |
| SCHEMBL51663 | 0.91 | PIM1 (0.85) | PIM1CSNK1DPARP1KMT2A | |
| SCHEMBL29496129 | 0.91 | PIM1 (1.00) | PIM1CSNK1DPARP1 | |
| SCHEMBL51064 | 0.91 | PIM1 (1.00) | PIM1CSNK1DPARP1 | |
| SCHEMBL1318823 | 0.90 | PIM1 (0.78) | PIM1CSNK1DPARP1KMT2A | |
| SCHEMBL13097393 | 0.90 | PIM1 (0.78) | PIM1CSNK1DPARP1KMT2A | |
| SCHEMBL1319786 | 0.90 | PIM1 (0.84) | PIM1CSNK1DPARP1 | |
| SCHEMBL51776 | 0.89 | PIM1 (0.82) | PIM1CSNK1DPARP1KMT2A | |
| SCHEMBL62121 | 0.88 | PARP1 (1.00) | PIM1CSNK1DPARP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883787-B2 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8470825-B2 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC. (US) | 2012-12-06 | — | — | US | disclosed |
| EP-1633362-B1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120115873-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | EISAI INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8058275-B2 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110092478-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | EISAI INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-7456178-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080058325-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | MGI GP, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7268138-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2007-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058325-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | PIM1 1226/4885CSNK1D 2063/4885PARP1 1/4885 |
| US-20120115873-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | PIM1 745/4885CSNK1D 3002/4885PARP1 1/4885 |
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | PIM1 1069/4885CSNK1D 2130/4885PARP1 1/4885 |
| US-20110092478-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | PIM1 622/4885CSNK1D 3185/4885PARP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.